Skip to content

Twitter page opens in new window Linkedin page opens in new window Instagram page opens in new window

info@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

June 30, Top 20 Shareholders

June 30, Top 20 Shareholders

Categories: News and Announcements 2021, Top 20 ShareholdersBy Richard Mollard July 1, 2021

Related posts

May 1, Top 20 Shareholders
May 1, 2022

April 1, Top 20 Shareholders
April 1, 2022

March 1, Top 20 Shareholders
March 1, 2022

February 1, Top 20 Shareholders
February 1, 2022

January 1, Top 20 Shareholders
January 1, 2022

December 15, Epichem Awarded DNDi Extension
December 15, 2021

Recent Articles

May 11, PharmAust Expands Canine Trial to the US
May 11, 2022
May 1, Top 20 Shareholders
May 1, 2022
April 29, Appendix 4C and Quarterly Update
April 29, 2022
April 19, PharmAust Receives $708k R&D Tax Rebate
April 19, 2022

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAustFollow

PharmAust is a clinical-stage biotech company developing drug discovery IP to treat cancer, viral and neurological diseases. ASX: $PAA FSE: $ECQ

Retweet on Twitter PharmAust Retweeted

Neale Daniher @NealeDaniher·

This is why we fight... to ensure that the next generation lives in a world without MND.

Join the fight to find effective treatments and a cure: https://bit.ly/3syzGRA @FightMND

Reply on Twitter 1529336978768265217 Retweet on Twitter 152933697876826521737 Like on Twitter 1529336978768265217910 Twitter 1529336978768265217

Copyright © 2020 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions